Singular Location and Signaling Profile of Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Dorsal Striatum

Neuropsychopharmacology

Volumn 43, Issue 5, 2018, Pages 964-977

  Moreno, Estefanía ^a,b   Chiarlone, Anna ^a,c,d   Medrano, Mireia ^a,b   Puigdellívol, Mar ^e   Bibic, Lucka ^e   Howell, Lesley A ^e,f   Resel, Eva ^a,c,d   Puente, Nagore ^g,h   Casarejos, María J ^d   Perucho, Juan ^d   Botta, Joaquín ^e   Suelves, Nuria ^a,b   Ciruela, Francisco ^b   Ginés, Silvia ^a,b   Galve Roperh, Ismael ^a,c,d   Casadó, Vicent ^a,b   Grandes, Pedro ^g,h   Lutz, Beat ⁱ   Monory, Krisztina ⁱ   Canela, Enric I ^a,b   Lluís, Carmen ^a,b   McCormick, Peter J ^a,b,e,j   Guzmán, Manuel ^a,c,d   more..

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

^e UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^h ACHUCARRO BASQUE CENTER FOR NEUROSCIENCE   (Spain)

ⁱ UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^j UNIVERSITY OF SURREY   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ADENOSINE A2A RECEPTOR; CANNABINOID 1 RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HUNTINGTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; ASSAY; COMPARATIVE STUDY; CONCEPTUAL FRAMEWORK; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DORSAL STRIATUM; GENE AMPLIFICATION; GLUTAMATERGIC SYNAPSE; HEK293T CELL LINE; HUNTINGTON CHOREA; MOUSE; NERVE CELL EXCITABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SCANNING ELECTRON MICROSCOPY; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; CORPUS STRIATUM; HUMAN; METABOLISM; NERVE TRACT; PROTEIN QUATERNARY STRUCTURE; PROTEIN SUBUNIT;

ANIMALS; CORPUS STRIATUM; HUMANS; HUNTINGTON DISEASE; MICE; NEURAL PATHWAYS; PROTEIN STRUCTURE, QUATERNARY; PROTEIN SUBUNITS; RECEPTOR, ADENOSINE A2A; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION;

EID: 85012884742     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2017.12     Document Type: Article

References (63)

1. Araki KY, Fujimura S, MacDonald ME, Bhide PG (2006). Characterization of mouse striatal precursor cell lines expressing functional dopamine receptors. Dev Neurosci 28: 518-527.
2. Azdad K, Gall D,Woods AS, Ledent C, Ferre S, Schiffmann SN (2009). Dopamine D2 and adenosine A2A receptors regulate NMDAmediated excitation in accumbens neurons through A2A-D2 receptor heteromerization. Neuropsychopharmacology 34: 972-986.
3. Bellocchio L, Lafenetre P, Cannich A, Cota D, Puente N, Grandes P et al (2010). Bimodal control of stimulated food intake by the endocannabinoid system. Nat Neurosci 13: 281-283.
4. Blazquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E et al (2011). Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 134: 119-136.
5. Bonaventura J, Navarro G, Casado-Anguera V, Azdad K, Rea W, Moreno E et al (2015). Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer. Proc Natl Acad Sci USA 112: E3609-E3618.
6. Bonaventura J, Rico AJ, Moreno E, Sierra S, Sanchez M, Luquin N et al (2014). L-DOPA-treatment in primates disrupts the expression of A2A adenosine-CB1 cannabinoid-D2 dopamine receptor heteromers in the caudate nucleus. Neuropharmacology 79: 90-100.
7. Cabello N, Gandia J, Bertarelli DC, Watanabe M, Lluis C, Franco R et al (2009). Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells. J Neurochem 109: 1497-1507.
8. Carriba P, Ortiz O, Patkar K, Justinova Z, Stroik J, Themann A et al (2007). Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology 32: 2249-2259.
9. Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y (2012). Endocannabinoid signaling and synaptic function. Neuron 76: 70-81.
10. Ciruela F, Casado V, Rodrigues RJ, Lujan R, Burgueno J, Canals M et al (2006). Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci 26: 2080-2087.
11. Chiarlone A, Bellocchio L, Blazquez C, Resel E, Soria-Gomez E, Cannich A et al (2014). A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Proc Natl Acad Sci USA 111: 8257-8262.
12. Chiodi V, Ferrante A, Ferraro L, Potenza RL, Armida M, Beggiato S et al (2016). Striatal adenosine-cannabinoid receptor interactions in rats overexpressing adenosine A2 receptors. J Neurochem 136: 907-917.
13. Chiodi V, Uchigashima M, Beggiato S, Ferrante A, Armida M, Martire A et al (2012). Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease. Neurobiol Dis 45: 983-991.
14. Chou SY, Lee YC, Chen HM, Chiang MC, Lai HL, Chang HH et al (2005). CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J Neurochem 93: 310-320.
15. De Salas-Quiroga A, Diaz-Alonso J, Garcia-Rincon D, Remmers F, Vega D, Gomez-Canas M et al (2015). Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB1 receptors on developing cortical neurons. Proc Natl Acad Sci USA 112: 13693-13698.
16. Denovan-Wright EM, Robertson HA (2000). Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience 98: 705-713.
17. Domenici MR, Scattoni ML, Martire A, Lastoria G, Potenza RL, Borioni A et al (2007). Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice. Neurobiol Dis 28: 197-205.
18. Fernandez-Ruiz J, Moreno-Martet M, Rodriguez-Cueto C, Palomo-Garo C, Gomez-Canas M, Valdeolivas S et al (2011). Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol 163: 1365-1378.
19. Ferrada C, Moreno E, Casado V, Bongers G, Cortes A, Mallol J et al (2009). Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors. Br J Pharmacol 157: 64-75.
20. Ferre S, Lluis C, Justinova Z, Quiroz C, Orru M, Navarro G et al (2010). Adenosine-cannabinoid receptor interactions. Implications for striatal function. Br J Pharmacol 160: 443-453.
21. Ferreira SG, Goncalves FQ, Marques JM, Tome AR, Rodrigues RJ, Nunes-Correia I et al (2015). Presynaptic adenosine A2A receptors dampen cannabinoid CB1 receptor-mediated inhibition of corticostriatal glutamatergic transmission. Br J Pharmacol 172: 1074-1086.
22. Girault JA (2012). Integrating neurotransmission in striatal medium spiny neurons. Adv Exp Med Biol 970: 407-429.
23. Glass M, Dragunow M, Faull RL (2000). The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97: 505-519.
24. Guitart X, Navarro G, Moreno E, Yano H, Cai NS, Sanchez-Soto M et al (2014). Functional selectivity of allosteric interactions within G protein-coupled receptor oligomers: the dopamine D1-D3 receptor heterotetramer. Mol Pharmacol 86: 417-429.
25. He SQ, Zhang ZN, Guan JS, Liu HR, Zhao B, Wang HB et al (2011). Facilitation of mu-opioid receptor activity by preventing deltaopioid receptor-mediated codegradation. Neuron 69: 120-131.
26. Hua T, Vemuri K, Pu M, Qu L, Han GW, Wu Y et al (2016). Crystal structure of the human cannabinoid receptor CB1. Cell 167: 750-762.
27. Huang NK, Lin JH, Lin JT, Lin CI, Liu EM, Lin CJ et al (2011). A new drug design targeting the adenosinergic system for Huntington's disease. PLoS One 6: e20934.
28. Justinova Z, Redhi GH, Goldberg SR, Ferre S (2014). Differential effects of presynaptic versus postsynaptic adenosine A2A receptor blockade on delta-9-tetrahydrocannabinol (THC) self-administration in squirrel monkeys. J Neurosci 34: 6480-6484.
29. Katona I, Freund TF (2008). Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 14: 923-930.
30. Kreitzer AC (2009). Physiology and pharmacology of striatal neurons. Annu Rev Neurosci 32: 127-147.
31. Kreitzer AC, Malenka RC (2005). Dopamine modulation of statedependent endocannabinoid release and long-term depression in the striatum. J Neurosci 25: 10537-10545.
32. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ et al (1997). Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388: 674-678.
33. Lee CF, Chern Y (2014). Adenosine receptors and Huntington's disease. Int Rev Neurobiol 119: 195-232.
34. Lee LT, Ng SY, Chu JY, Sekar R, Harikumar KG, Miller LJ et al (2014). Transmembrane peptides as unique tools to demonstrate the in vivo action of a cross-class GPCR heterocomplex. FASEB J 28: 2632-2644.
35. Lerner TN, Horne EA, Stella N, Kreitzer AC (2010). Endocannabinoid signaling mediates psychomotor activation by adenosine A2A antagonists. J Neurosci 30: 2160-2164.
36. Li W, Silva HB, Real J, Wang YM, Rial D, Li P et al (2015). Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington's disease models. Neurobiol Dis 79: 70-80.
37. Lovinger DM (2010). Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum. Neuropharmacology 58: 951-961.
38. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG et al (2002). The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: 530-534.
39. McCaw EA, Hu H, Gomez GT, Hebb AL, Kelly ME, Denovan-Wright EM (2004). Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. Eur J Biochem 271: 4909-4920.
40. Mievis S, Blum D, Ledent C (2011a). A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease. Neurobiol Dis 41: 570-576.
41. Mievis S, Blum D, Ledent C (2011b). Worsening of Huntington disease phenotype in CB1 receptor knockout mice. Neurobiol Dis 42: 524-529.
42. Monory K, Blaudzun H, Massa F, Kaiser N, Lemberger T, Schutz G et al (2007). Genetic dissection of behavioural and autonomic effects of delta-9-tetrahydrocannabinol in mice. PLoS Biol 5: e269.
43. Monory K, Massa F, Egertova M, Eder M, Blaudzun H, Westenbroek R et al (2006). The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51: 455-466.
44. Navarro G, Carriba P, Gandia J, Ciruela F, Casado V, Cortes A et al (2008). Detection of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-protein-coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer. ScientificWorldJournal 8: 1088-1097.
45. Navarro G, Ferre S, Cordomi A, Moreno E, Mallol J, Casado V et al (2010). Interactions between intracellular domains as key determinants of the quaternary structure and function of receptor heteromers. J Biol Chem 285: 27346-27359.
46. Nelson AB, Kreitzer AC (2014). Reassessing models of basal ganglia function and dysfunction. Annu Rev Neurosci 37: 117-135.
47. Orru M, Zanoveli JM, Quiroz C, Nguyen HP, Guitart X, Ferre S (2011). Functional changes in postsynaptic adenosine A2A receptors during early stages of a rat model of Huntington disease. Exp Neurol 232: 76-80.
48. Quiroz C, Lujan R, Uchigashima M, Simoes AP, Lerner TN, Borycz J et al (2009). Key modulatory role of presynaptic adenosine A2A receptors in cortical neurotransmission to the striatal direct pathway. ScientificWorldJournal 9: 1321-1344.
49. Ruehle S, Remmers F, Romo-Parra H, Massa F, Wickert M, Wortge S et al (2013). Cannabinoid CB1 receptor in dorsal telencephalic glutamatergic neurons: distinctive sufficiency for hippocampus-dependent and amygdala-dependent synaptic and behavioral functions. J Neurosci 33: 10264-10277.
50. Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferre S (2007). Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol 83: 277-292.
51. Schiffmann SN, Vanderhaeghen JJ (1993). Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J Neurosci 13: 1080-1087.
52. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999). In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 1569-1572.
53. Shao Z, Yin J, Chapman K, Grzemska M, Clark L, Wang J et al (2016). High-resolution crystal structure of the human CB1 cannabinoid receptor. Nature [Epub ahead of print].
54. Shoichet BK, Kobilka BK (2012). Structure-based drug screening for G-protein-coupled receptors. Trends Pharmacol Sci 33: 268-272.
55. Taura J, Fernandez-Duenas V, Ciruela F (2015). Visualizing G proteincoupled receptor-receptor interactions in brain using proximity ligation in situ assay. Curr Protoc Cell Biol 67: 17 17 11-16.
56. Tebano MT, Martire A, Popoli P (2012). Adenosine A2A-cannabinoid CB1 receptor interaction: an integrative mechanism in striatal glutamatergic neurotransmission. Brain Res 1476: 108-118.
57. Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp AH, Persichetti F et al (2000). Dominant phenotypes produced by the HD mutation in STHdhQ111 striatal cells. Hum Mol Genet 9: 2799-2809.
58. Uchigashima M, Narushima M, Fukaya M, Katona I, Kano M, Watanabe M (2007). Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci 27: 3663-3676.
59. Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, Babu MM (2013). Molecular signatures of G-protein-coupled receptors. Nature 494: 185-194.
60. Viñals X, Moreno E, Lanfumey L, Cordomi A, Pastor A, de La Torre R et al (2015). Cognitive impairment induced by delta-9-tetrahydrocannabinol occurs through heteromers between cannabinoid CB1 and serotonin 5-HT2A receptors. PLoS Biol 13: e1002194.
61. Walker FO (2007). Huntington's disease. Lancet 369: 218-228.
62. Xu F, Wu H, Katritch V, Han GW, Jacobson KA, Gao ZG et al (2011). Structure of an agonist-bound human A2A adenosine receptor. Science 332: 322-327.
63. Yin HH, Lovinger DM (2006). Frequency-specific and D2 receptormediated inhibition of glutamate release by retrograde endocannabinoid signaling. Proc Natl Acad Sci USA 103: 8251-8256.